These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 37945490)

  • 1. The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study.
    Inoue Y; Li Y; Yamamoto S; Fukunaga A; Ishiwari H; Ishii M; Miyo K; Ujiie M; Sugiura W; Ohmagari N; Mizoue T
    Vaccine; 2023 Nov; 41(49):7317-7321. PubMed ID: 37945490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
    Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
    PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan.
    Kanai D; Wakui H; Haze T; Azushima K; Kinguchi S; Tsukamoto S; Kanaoka T; Urate S; Toya Y; Hirawa N; Kato H; Watanabe F; Hanaoka K; Hanaoka M; Mitsuhashi H; Yamaguchi S; Ohnishi T; Tamura K
    Clin Exp Nephrol; 2022 Oct; 26(10):988-996. PubMed ID: 35751753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between use of antipyretics and antibody titers after two doses of the BNT162b2 SARS-CoV-2 vaccine in adolescents and young adults with underlying diseases.
    Aiba H; Funaki T; Yamada M; Miyake K; Ueno S; Tao C; Myojin S; Matsui T; Ogimi C; Kato H; Miyairi I; Shoji K
    J Infect Chemother; 2024 Feb; 30(2):176-178. PubMed ID: 37769991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection.
    Tyner HL; Burgess JL; Grant L; Gaglani M; Kuntz JL; Naleway AL; Thornburg NJ; Caban-Martinez AJ; Yoon SK; Herring MK; Beitel SC; Blanton L; Nikolich-Zugich J; Thiese MS; Pleasants JF; Fowlkes AL; Lutrick K; Dunnigan K; Yoo YM; Rose S; Groom H; Meece J; Wesley MG; Schaefer-Solle N; Louzado-Feliciano P; Edwards LJ; Olsho LEW; Thompson MG
    Clin Infect Dis; 2022 Aug; 75(1):e827-e837. PubMed ID: 34928334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of heated tobacco products, moderate alcohol drinking, and anti-SARS-CoV-2 IgG antibody titers after BNT162b2 vaccination among Japanese healthcare workers.
    Yamamoto S; Tanaka A; Ohmagari N; Yamaguchi K; Ishitsuka K; Morisaki N; Kojima M; Nishikimi A; Tokuda H; Inoue M; Tanaka S; Umezawa J; Okubo R; Nishimura K; Konishi M; Miyo K; Mizoue T
    Prev Med; 2022 Aug; 161():107123. PubMed ID: 35787841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.
    Matsuura T; Fukushima W; Nakagama Y; Kido Y; Kase T; Kondo K; Kaku N; Matsumoto K; Suita A; Komiya E; Mukai E; Nitahara Y; Konishi A; Kasamatsu A; Nakagami-Yamaguchi E; Ohfuji S; Kaneko Y; Kaneko A; Kakeya H; Hirota Y
    Vaccine; 2022 Sep; 40(38):5631-5640. PubMed ID: 36028457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients.
    Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T
    Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depressive symptoms predict antibody titers after a second dose of the SARS-CoV-2 BNT162b2 vaccine among hospital workers in Japan.
    Kaneko H; Tsuboi H
    Brain Behav Immun; 2023 Jan; 107():414-418. PubMed ID: 36116693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study.
    Jubishi D; Okamoto K; Hamada K; Ishii T; Hashimoto H; Shinohara T; Yamashita M; Wakimoto Y; Otani A; Hisasue N; Ikeda M; Harada S; Okugawa S; Moriya K; Yanagimoto S
    Hum Vaccin Immunother; 2022 Nov; 18(5):2048559. PubMed ID: 35333697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines.
    Hickey TE; Kemp TJ; Bullock J; Bouk A; Metz J; Neish A; Cherry J; Lowy DR; Pinto LA
    Hum Vaccin Immunother; 2023 Aug; 19(2):2215677. PubMed ID: 37264688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidemia and SARS-CoV-2 spike antibody titres after the second and third doses of the BNT162b2 vaccine among healthcare workers in Japan.
    Islam Z; Yamamoto S; Mizoue T; Oshiro Y; Inamura N; Konishi M; Ozeki M; Sugiura W; Ohmagari N
    Diabetes Metab Res Rev; 2023 Mar; 39(3):e3606. PubMed ID: 36562447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study.
    Leong DP; Zhang A; Breznik JA; Clare R; Huynh A; Mushtaha M; Rangarajan S; Stacey H; Kim PY; Loeb M; Denburg JA; Mertz D; Chagla Z; Nazy I; Miller MS; Bowdish DME; Duong M
    PLoS One; 2023; 18(2):e0281673. PubMed ID: 36791069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-vaccination antibody evaluation for nosocomial SARS-CoV-2 delta variant breakthrough infection.
    Goto T; Tani N; Ikematsu H; Gondo K; Oishi R; Minami J; Onozawa K; Kuwano H; Akashi K; Shimono N; Chong Y
    PLoS One; 2022; 17(7):e0272056. PubMed ID: 35877668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.